The fourth CGRP migraine drug is here. Time for Lundbeck to prove it’s worth $2B

They may be late, but Lundbeck is now officially in the game for preventing migraine with CGRP drugs.

The FDA has OK?d eptinezumab, the prize in Lundbeck?s $2 billion acquisition of Alder. Like rival offerings from Amgen/Novartis, Eli Lilly and Teva, the antibody blocks the calcitonin gene-related peptide, which is believed to dilate blood vessels in the brain and cause pain.

It will now be sold as Vyepti. The company has yet to announce a price.?Amgen and Novartis had set the wholesale acquisition cost of their pioneering Aimovig at $6,900 for a year?s supply before raising it slightly this year; Lilly and Teva had followed suit with Emgality and Ajovy.

Click to view original post